Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
InSightec
InSightec
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
Case Comprehensive Cancer Center
Amgen
University of Texas Southwestern Medical Center
Acerta Pharma BV
Hoffmann-La Roche
Inovio Pharmaceuticals
University of Florida
Hoffmann-La Roche
Genenta Science
Sapience Therapeutics
Cantex Pharmaceuticals
Pediatric Brain Tumor Consortium
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
AstraZeneca
Black Diamond Therapeutics, Inc.
AstraZeneca
Massachusetts Eye and Ear Infirmary
Memorial Sloan Kettering Cancer Center
Centre Francois Baclesse
Washington University School of Medicine
Universitair Ziekenhuis Brussel
GlaxoSmithKline
M.D. Anderson Cancer Center
Guangzhou Medical University
Institut Curie
Nerviano Medical Sciences
Baylor College of Medicine
TME Pharma AG
University of Pittsburgh
Heron Neutron Medical Corp.
Memorial Sloan Kettering Cancer Center
Institute of Cancer Research, United Kingdom
In8bio Inc.
West Virginia University
Centre Jean Perrin
Bambino Gesù Hospital and Research Institute
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
University of Louisville
NGM Biopharmaceuticals, Inc
University Hospital, Antwerp